You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
|
|---|---|
| Published in |
Annals of Oncology, April 2016
|
| DOI | 10.1093/annonc/mdw164 |
| Pubmed ID | |
| Authors |
T. Tandstad, O. Ståhl, O. Dahl, H.S. Haugnes, U. Håkansson, Å. Karlsdottir, A. Kjellman, C.W. Langberg, A. Laurell, J. Oldenburg, A. Solberg, K. Söderström, U. Stierner, E. Cavallin-Ståhl, R. Wahlqvist, N. Wall, G. Cohn-Cedermark, on behalf of SWENOTECA |
| Abstract |
The purpose of the protocol was to reduce the treatment burden in clinical stage I (CS I) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, stromal invasion of the rete testis and tumor diameter >4cm, and to evaluate the efficacy of one course of adjuvant carboplatin. From 2007-2010, 897 patients were included in a prospective, population-based, risk-adapted treatment protocol implementing one course of adjuvant carboplatin AUC7 (n=469) or surveillance (n=422). In addition, results from 221 patients receiving carboplatin between 2004-2007 are reported. At a median follow-up of 5.6 years, 69 relapses have occurred. Stromal invasion of the rete testis (HR 1.9, p=0.011) and tumor diameter >4 cm (HR 2.7, p<0.001) were identified as risk factor predicting relapse. In patients without risk factors the relapse rate (RR) was 4.0% for patients managed by surveillance compared to 2.2% in patients receiving adjuvant carboplatin. In patients with one or two risk factors the RR was 15.5% in patients managed by surveillance compared to 9.3% in patients receiving adjuvant carboplatin. We found no increased RR in patients receiving carboplatin <7xAUC compared to patients receiving ≥7xAUC. Stromal invasion in the rete testis and tumor diameter >4 cm are risk factors for relapse in CSI seminoma. Patients without risk factors have a low RR and adjuvant therapy is not justified in these patients. The efficacy of adjuvant carboplatin is relatively low and there is need to explore more effective adjuvant treatment options in patients with high-risk seminoma. The data do not support the concept of a steep dose response for adjuvant carboplatin. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 25% |
| Spain | 1 | 13% |
| France | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
| Scientists | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 72 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 19% |
| Other | 12 | 17% |
| Student > Doctoral Student | 8 | 11% |
| Student > Postgraduate | 6 | 8% |
| Student > Ph. D. Student | 6 | 8% |
| Other | 9 | 13% |
| Unknown | 17 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 63% |
| Chemical Engineering | 1 | 1% |
| Biochemistry, Genetics and Molecular Biology | 1 | 1% |
| Sports and Recreations | 1 | 1% |
| Agricultural and Biological Sciences | 1 | 1% |
| Other | 2 | 3% |
| Unknown | 21 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2017.
All research outputs
#7,356,550
of 25,377,790 outputs
Outputs from Annals of Oncology
#3,741
of 7,854 outputs
Outputs of similar age
#98,634
of 315,714 outputs
Outputs of similar age from Annals of Oncology
#65
of 109 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 7,854 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,714 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 109 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.